We consider the FDA approved Glucose-Insulin-Glucagon nonlinear model which describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes. Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and glucagon (dual-therapy) that can optimally maintain the blood glucose level after consuming a meal within healthy limits and prevent the onset of both hypoglycemia and hyperglycemia. The problem is formulated as a nonlinear optimal control problem, which we solve using the numerical optimal control package PSOPT . Interestingly, in the case of monotherapy, the optimal solution we find is nearly identical to the standard method of insulin based glucose regulation, which is to assume a variable amount of insulin half an hour before each meal. We also find that the optimal dual-therapy (using both insulin and glucagon) is better able to regulate glucose as compared to using insulin alone. We also propose a rule for both dosage and time of delivery for the dual-therapy. Our results, which are optimal, can serve as a reference to evaluate the relative performance of alternative control algorithms that use the blood glucose model. arXiv:1810.04164v1 [q-bio.TO] 
Introduction
Insulin and glucagon are pancreatic hormones that help regulate the levels of glucose in the blood. Insulin is produced by beta-cells in the pancreas and carries glucose from the bloodstream to the cells throughout the body. Glucagon releases glucose from the liver into the bloodstream which helps to prevent hypoglycemia. In people affected by diabetes insulin is either absent (type I diabetes) or not produced in the proper amount (type II diabetes). In type I diabetes the body's immune system attacks and destroys the beta cells. As a result, insulin is not produced and glucose accumulates in the blood which may cause serious damage to several organs. Type II diabetes is a metabolic disorder in which the beta cells are unable to properly maintain the blood glucose. Common therapies for diabetes involve the administration of exogenous insulin. Currently glucagon is not used in typical diabetes therapies because glucagon does not preserve its chemical properties at room temperature and diabetic patients are still able to produce it.
The control of glucose levels in diabetic patients is an active field of research [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The approval by the FDA of a simulator which replaces in-vivo with in-silico therapy testing has greatly benefited this area of research. This simulator implements a mathematical model, first proposed in [16] and updated in [17, 18] , and provides an alternative to often slow, dangerous and expensive human testing.
Typically, insulin is administered manually approximately thirty minutes before each meal where the amount is determined from the current glucose level (measured through a blood sugar test), the expected glucose content to be eaten, and the patient's sensitivity to insulin. In what October 11, 2018 1/25 follows we will refer to this as the standard therapy. In 1992 the first insulin pumps were introduced to the market. They delivered both a consistent basal amount of insulin and an insulin bolus decided by the patients based on their glucose level. It was only in 2016 that the first autonomous system for glycemic control was approved by the FDA. The system consists of an insulin pump, a sensor that continuously measures the blood glucose level, and control software that together is able to regulate the insulin level in the blood without needing any input from the patient. Many control techniques have been proposed and tested to regulate blood glucose levels using insulin pumps including PID (proportional-integral-derivative) control [1, 2, [4] [5] [6] 19] , fuzzy logic control [7] [8] [9] and bio-inspired techniques [10] which do not rely on a mathematical model. In [20] , closed loop control has been used on a so called "minimal model" [21] [22] [23] . In [11] [12] [13] [14] 24 ], a linear model predictive control (MPC) has been used where, while the model's structure is known, the parameters are constantly updated to adapt to the patient's reaction. In [25] MPC has been applied to a system linearized around the operating points of a physically derived nonlinear model and in [26] multiple model probabilistic predictive control has been used. In [27] MPC has been applied together with a moving horizon estimation technique to a linear model. Most of the models used when designing the above controllers are simplified versions of the FDA approved model and all the control techniques considered only use insulin (but not glucagon) as control input.
Because insulin delivered exogenously is not subject to normal physiological feedback regulation, hypoglycemia is common in patients with Type 1 diabetes who undergo treatment [28] . For these patients it has been proposed that exogenous insulin can be used to lower the blood glucose level and exogenous glucagon can be used to prevent hypoglycemia [29] . Currently, a commercial pump that delivers both insulin and glucagon is not available, and the development of a two-drug artificial pancreas is still the subject of clinical research [30] [31] [32] [33] [34] [35] [36] . Precisely how and when insulin and glucagon should be jointly supplied remains an outstanding research question.
Following the study in [37] which optimized multi-drug therapies for autophagy regulation, here we try to find an optimal insulin and glucagon therapy. We consider the combined effects of insulin and glucagon in regulating blood glucose levels in patients with Type 1 diabetes, using the FDA approved model in [18] and nonlinear optimal control theory. Additionally, the objective function that we look to minimize is the Blood Glucose Index which is a well known tool to measure at how much risk a patient is of either hyperglycemia or hypoglycemia. To design the optimal control problem, we use the balance control technique studied in [38] , which introduces a trade-off between the error allowed with respect to a state based cost (Blood Glucose Index) and the control effort. Our goal is to evaluate the performance limits of a control algorithm in the blood glucose problem, and to discuss the advantages of the dual drug therapy compared to the one drug therapy. Note that even though our scope is not to design a closed-loop control strategy that works without the patient's intervention, the solution we propose can be adapted for that purpose.
We see from solving the optimal control problem for a family of objective functions derived from the balance control paradigm, a pattern emerges from which we construct a rule for the proper delivery of insulin and glucagon similar to the standard therapy when insulin is used alone. While this therapy suggested is suboptimal, we see that it still performs better than the optimal solution with insulin alone.
Finally, we test the robustness of the optimal solution. By its formulation, optimal control does not guarantee any robustness with respect to model uncertainty or parameter mismatch. Despite this, we see that the control computed is able to regulate the glucose level well even when we perturb the model's parameters.
Materials and methods

Model and Parameters
We consider the model in [17, 18] which is a system of nonlinear ordinary differential equations (ODEs). The equations are given in Eqs. (S1)-(S9) in supplementary information section S1. We write the ODEs in Eqs. (S1)-(S9) in the forṁ
where the state vector is x = [x 1 (t), x 2 (t), ..., x 17 (t)] T and t is the physical time (in min). In Table 1 we tabulate all of the variables x i and their names. The control input vector is
where u I (t) ≥ 0 is the exogenous insulin infusion rate (in insulin Unit/min) and u G (t) ≥ 0 is the exogenous glucagon infusion rate (mg/min). Both u I (t) and u G (t) are the external inputs to the system in Eq. (1). The scalar quantity D(t) represents the exogenous glucose input, that is, the glucose intake with a meal. The output of the system is the quantity G(t), which measures the density of glucose in the blood, obtained as the ratio between the plasma glucose and the distribution volume of glucose V G . When u I (t) = 0, u G (t) = 0 and D(t) = 0, the model reaches (for physically meaningful parameters) a steady state, also known as the basal condition of a patient. The basal condition depends upon the parameters of the models Θ. We denote by Θ G b the set of parameters for which the basal glucose level G is equal to G b . The basal levels for the other states are found according to the Eqs. (S11). 
Problem Formulation
We formulate a nonlinear optimal control problem with two control goals. The first goal is to regulate the glucose at levels corresponding to low clinical risk (of hyperglycemia or hypoglycemia) during a time period over which a meal is consumed. We assume that a meal is ingested at time t = τ D , which we assume to be modeled as a Dirac delta function
To evaluate the clinical risk of a particular glycemic value, Kovatchev et al. [39, 40] proposed the Blood Glucose Index (BGI), defined as BGI (G(t)) = 10 1.509 (ln G(t)) 1.084 − 5.3811 2 ,
where a small BGI value corresponds to low risk of either hyperglycemia or hypoglycemia. This metric also takes into account the fact that (i) the target blood glucose range as defined by the diabetes control and complications trial [41] (between 70 and 180 mg/dL) is not symmetric about the center of the range and (ii) hypoglycemia occurs at glucose levels closer to the basal level than hyperglycemia. The second goal is to limit the usage of insulin and/or glucagon over the period [t 0 , t f ]. We formulate the optimization problem according to these two goals,
subject to the following constraints,
In Eqs. (2) and (3), the insulin infusion rate u I (t) and the glucagon infusion rate u G (t) are the two control inputs. The three coefficients α p , α I and α G in Eq. (2) are tunable factors through which we may vary the weight associated with each of the three terms in the cost function J. The first coefficient, α p , is dimensionless while the units of α I and α G are (U/min) −p and (mg/min) −p , respectively. Note that by setting u U G = 0 in Eq. (3d), we have an optimal control problem in terms of insulin only.
The first term in the objective function (2) defines a regulation problem, i.e., we try to maintain the glucose at low risk levels. The second and third terms in the cost function are chosen to avoid using excess insulin or glucagon. For p = 1 in Eq. (2), the second and third terms define a 'minimum fuel' problem, thus we call the optimization problem ReMF (Regulation and Minimum Fuel). In this case, we expect the optimal solution to consist of pulsatile inputs u * I (t) and u * G (t) [42, 43] . For p = 2, the second and third term inside the cost function define a 'minimum energy' problem, thus we call the optimization problem ReME (Regulation and Minimum Energy). In this case, we expect the optimal control inputs u * I (t) and u * G (t) to be continuous. The set of equations in (3a) are the ODEs in Eqs. (S1)-(S9). In Eq. (3b) G L and G U are the lower and upper bounds for G(t). They can be set in order to avoid undesired hypoglycemic or hyperglycemic states. In Eqs. (3c) and (3d) u U I and u U G are upper bounds for the insulin and glucagon delivery rates, respectively. These constraints are set by the maximum infusion rates allowed by the insulin pump. In Eq. (3c) u L I ≥ 0 is the lower bound for u I (t), i.e., a minimum delivery rate for insulin that can be used to set a basal insulin infusion rate to counteract endogenous glucose production [44] . Finally, in Eqs. (3e, 3f), φ U I and φ U G set a limit to the total amount of insulin and glucagon that can be delivered over the time period [t 0 , t f ]. The initial conditionx in Eq. (3g) defines the patient's condition before we start to administrate the therapy. In the Results section, we discuss how we choose the bounds on G(t), u I (t), u G (t), φ I , φ G , the control time period [t 0 , t f ] and the initial conditionx.
Our goal is to find an optimal solution which satisfies the constraints in Eq. (3) and minimizes the objective function (2) . Note that the BGI only depends upon G(t): we are making no attempt to control the states of the system, only its output. In the literature, such an approach is often referred to as target control [42, 45] .
Method: Pseudo-Spectral Optimal Control
Optimal control theory combines aspects of dynamical systems, optimization, and the calculus of variations [42] to solve the problem of finding a control law for a given dynamical system such that the prescribed optimality criteria are achieved. The equations (2) and (3) together form a constrained optimal control problem, which can generally be written as,
In general, there exists no analytic framework that is able to provide the optimal time traces of the controls u * (t) and the states x * (t) in (4), and so we must resort to numerical techniques.
Pseudo-Spectral Optimal Control (PSOC) is a computational method for solving optimal control problems. Here we present a brief overview of the theory of pseudo-spectral optimal control. PSOC has become a popular tool in recent years [46, 47] that has let scientists and engineers solve optimal control problems like (4) reliably and efficiently in applications such as guiding autonomous vehicles and maneuvering the international space station [47] . PSOC is an approach by which an OCP can be discretized by approximating the integrals by quadratures and the time-varying states and control inputs with interpolating polynomials. Here we summarize the main concept of the PSOC. We choose a set of N discrete times {τ i } i = 0, 1, . . . , N where τ 0 = −1 and τ N = 1 with a mapping between t ∈ [t 0 , t f ] and τ ∈ [−1, 1]. The times {τ i } are chosen as the roots of an (N + 1)th order orthogonal polynomial such as Legendre polynomials or Chebyshev polynomials. The choice of dicretization scheme is important to the convergence of the full discretized problem. For instance, if we choose the roots of a Legendre polynomial as the discretization scheme, the associated quadrature weights can be found in the typical way for Gauss quadrature. The time-varying states and control inputs are found by approximating them with Lagrange interpolating polynomials,
wherex(τ ) andû(τ ) are the approximations of x(τ ) and u(τ ), respectively, and L i (τ ) is the ith Lagrange interpolating polynomial. The dynamical system is approximated by differentiating the approximationx(τ ) = N i=0x i L i (τ ) with respect to time.
Let D k,i = d dτ L i (τ k ) which allows one to rewrite the original dynamical system constraints in (4) as the following set of algebraic constraints.
The integral in the cost function is approximated as,
The original time-varying states, control inputs, the dynamical equations constrained and the cost function are now discretized approximation of the continuous NLP problem. Thus the discretized approximation of the original OCP is compiled into the following nonlinear programming (NLP) problem.
We have used PSOPT [48] , an open-source PSOC library, to perform the above PSOC discretization procedure. The NLP in (9) can be solved with a number of different techniques, but here we use an interior point algorithm [49] as implemented in the open-source software Ipopt [50] .
Continuous Approximation of Non-differential Function in ODEs
The PSOC formulation requires that the derivative of the function f(x(t), u(t), Θ G b ) exists and so it must be smooth. As there are terms that contain discontinuities in Eqs. (S1)-(S9), we replace them with continuous approximations which are described in detail in SI section S2.
Results
We now describe in more detail the optimal control problem in Eqs. 2 and 3 setting the constraint and parameter values. In Fig. 1A we plot the BGI(G) as a function of the glucose G(t). The minimum BGI (G) occurs at G(t) = G d = 112.51 mg/dL, which corresponds to a clinical target set for the glucose level [41] . We assume that a Type I diabetic person has a high basal glucose level, say G b = 160 (mg/L). The parameters Θ G b are set so that the steady state glucose is 160 (mg/L) in the absence of a meal and insulin, i.e., we compute Θ 160 . We set the upper and lower bounds for the glucose level, G L and G U in Eq. (3b), to satisfy the target blood glucose range, 90 ≤ G(t) ≤ 180 [41] . The control time period is [t 0 , t f ] = [0, 300] minutes, and we assume that a meal with 70 grams of glucose is consumed at time t = 60 min (i.e., D(t) = 70δ(t − 60)).
We consider a situation in which the patient's glucose level is partially controlled by providing a constant but low insulin infusion rate u b > 0 (which is common for patients who use 
A) The Blood Glucose Index (BGI(G(t))) as a function of the blood glucose G(t). The function is minimized at G(t) = G d = 112.51 (mg/dL). B) The response of glucose (G(t)) to different time-constant basal insulin infusion rates in the absence of a meal. We see that as u b increases, the glucose is further down regulated.
an insulin pump) [44] : It serves to compensate for the endogenous glucose production. In figure  1B we show the response of glucose G(t) for different values of constant u b in the absence of a meal. We observe that for u b = 0.0107 (U/min), G(t) converges to the desired glucose level G d . We thus set the lower bound of u I (t) in Eq. (3c), u L I = u b , while its upper bound is set to u U I = 15 (in U/min), the maximum insulin flow allowed in commercial pumps [51] . In the absence of specialized commercially available glucagon pumps, we will assume a mechanically similar pump is used to deliver glucagon. Since the maximum flow rate for an insulin pump is 0.15 mL/min (1 mL of insulin solution contains 100 U of insulin), and normally 1 mg of glucagon is diluted in 1 mL of solution, the maximum glucagon flow rate in Eq. (3d) is set to u U G = 0.15 mg/min.
The amount of insulin administered in a bolus to a patient with a basal glucose level greater than 150 mg/dL normally ranges between 0.2 and 0.5 U/kg [52] . As the body mass of the in-silico patient we consider is 78 kg, we set φ U I = 40 U in Eq. (3e). The maximum total amount of glucagon administered in one shot to a patient who is in a hypoglycemic state is 1 mg, and a second identical shot can be administered after half an hour. We thus choose the maximum total amount of glucagon used (as defined in Eq. (3f)) throughout the five hour therapy to be φ U G = 1mg.
The choice of the initial conditionx in Eq. (3g) is critical. We select the initial condition so that the solution of our optimal control problem only attempts to regulate glucose in response to a meal. In the results presented we have set the initial condition equal to the values of the states when u I (t) = u b after a period of fasting (the final point of the blue curve in Fig. 1B ). If we were to select any alternative initial condition then the solution to the optimal control problem will try to 'correct' the initial condition as well, making comparisons between solutions difficult.
Once the parameters, bounds, the control time period and the initial condition are set, we solve the nonlinear optimal control problem using PSOPT , briefly described in the Method subsection. We first solve the optimal control problem without glucagon (i.e., u U G = 0), and then second we solve the optimal control problem with both insulin and glucagon.
To evaluate the effectiveness of the obtained results, we introduce the following measures.
• The cumulative insulin r I (t) and cumulative glucagon r G (t) used up to time t,
• The total amount of insulin φ I = r I (t f ) and the total amount of glucagon φ G = r G (t f ) used over the entire time period.
• The integral of BGI over the entire duration,
where a big ∆ implies that the patient is at more risk of either hyperglycemia or hypoglycemia for a prolonged period of time.
• The maximum and minimum values attained by the blood glucose level over the entire duration,
which provide a measure of one's risk of hypoglycemia and hyperglycemia [40, 53] , respectively.
Insulin as Control Input
In this section we use only insulin as the control input, i.e., we set u U G = 0 in Eq. (3a). As the orders of magnitude of the two remaining terms in the objective function are different, it is important to find the appropriate values of the scaling factors α p and α I . In what follows, we use a Pareto-front analysis to determine these values. We first rewrite the objective function as
where ε = α p /α I . In Figs. 2(A-D) we plot ∆, G min , G max and φ I as functions of the objective function coefficient ε. By looking at these plots, we see that the four measures can be divided into two groups. On the one hand, ∆ and G max (panels A and C), improve (decrease) as ε is increased, with a sharp transition around ε = 1 for the ReMF problem and around ε = 10 for the ReME problem while on the other hand, G min and φ I (panels B and D), behave in the opposite way, i.e., they improve (decrease for insulin and increase for the minimum glucose level) as ε is decreased, again with a sharp transition around ε = 1 for the ReMF problem and around ε = 10 for the ReME problem. Because the four curves in Figs. 2(A-D) are monotone, all the points are Pareto-efficient, i.e., it is not possible to improve one objective (e.g., ∆) without worsening the other one (e.g., φ I ). We notice that past a certain value of ε (10 2 in the ReMF case, 10 4 in the ReME case) ∆ and G max do not further decrease and G min and φ I remain unchanged. We choose as weights α p = 10 2 and α I = 1 for p = 1 while we choose α p = 10 4 and α I = 1 for p = 2 (indicated by dashed circles in Fig. 2 ). The reason for this choice is that these values yield φ I ∼ 20 units, which is equal to half the maximum amount of insulin that can be supplied (φ U I ), and G min ∼ 95mg/dL, which is far from the hypoglycemic risk region.
In Fig. 2E , we plot a projection of the Pareto front into the ∆ and φ I plane. Looking at this plot, the trade-off between ∆ and φ I is evident; if the total amount of insulin expenditure is increased ∆ is decreased and vice-versa. The ReMF and the ReME therapies can also be compared in Fig. 2E . The ReMF Pareto front dominates the ReME one (both ∆ and φ I are lower on the blue curve (p = 1) compared to the magenta curve (p = 2)). This indicates that an insulin shot therapy (the optimal solution of a ReMF problem is typically a pulsatile function) gives better results in terms of ∆ than a therapy in which the drug is delivered over a longer period of time while using less insulin. Figure 3 shows the results of the optimal control problem for the selected values of α p and α I . The blue and magenta curves are the optimal solutions of the ReMF and of the ReME problem, respectively. The orange curve corresponds to the case that 20.88 U of insulin are injected 30 minutes before the time of the meal, i.e., the standard therapy.
We observe that for p = 1 the optimal insulin infusion rate is pulsatile with a pulse appearing at t = 26 minutes, which is 34 minutes before the time of the meal. It is incredible that the 10 −2 10 0 10 2 10 4 10 6 10 1 Performance of the optimal control solution as a function of ε. Large (small) values of ε correspond to a large (small) weight associated with the BGI index in the objective function, compared to the weight for insulin expenditure. The first four plots show our metrics as functions of the objective function coefficients: A) ∆ vs. ε, B) G min vs. ε, C) G max vs. ε, and D) φ I vs. ε. E) We also project the Pareto front into the ∆ -φ I plane. We see a clear trade-off between ∆ and φ I as we vary ε. By increasing ε we can decrease the values of ∆ and G max . However, the values of ∆ and G max do not further decrease for ε larger than 10 2 for the ReMF problem (p = 1) and the value of ∆ does not further decrease for ε larger than 10 4 for the ReME problem (p = 2). We choose ε = 10 2 for p = 1 and ε = 10 4 for p = 2, which are indicated by dashed circles in the figure, for the remaining simulations.
optimal solution is nearly equal to the standard insulin based therapy for glucose regulation in diabetics. The optimal insulin infusion rate is continuous when we solve the ReME problem, also shown in the inset of Fig. 3B . Note that the ReMF and ReME therapies perform very similarly with respect to glucose as the peak insulin infusion rate occurs at approximately the same moment and the total amount of insulin administered is nearly equal.
Insulin and Glucagon as Control Inputs
In the previous section we have tuned the weights α p and α I inside the objective function (2) . We now consider the case that u U G > 0 and we tune α G , the weight associated with the glucagon expenditure in the objective function (2) .
In Fig. 4A, 4B and 4C, we plot the optimal ∆, G min and G max as functions of the parameter α G , respectively. A large value of α G indicates that we are placing a large weight on the expenditure of glucagon within the objective function (2), i.e., the larger the value of α G , we try to use less glucagon. By looking at Fig. 4A , we observe that the values of ∆ decrease as α G decreases, i.e., we can obtain lower (improved) values of ∆ if we allow for a larger expenditure of glucagon. We note that past a certain value of α G (10 −2 in the both the ReMF and ReME problems) no further reduction of ∆ is observed. As in the previous case, the maximum glucose value G max (Fig. 4C) improves (decreases) when ∆ improves (decreases). Interestingly, different from the previous case, also the minimum glucose level G min (Fig. 4C) improves (increases) with ∆ and G max : this is a consequence of the fact that we are using both insulin and glucagon as control inputs, thus we can simultaneously avoid both hypoglycemia and hyperglycemia.
In Fig. 4D we plot the projection of the Pareto front in the (φ I , φ G ) plane. The shape of the front shows a linear relationship between φ I and φ G . This is a consequence of the fact that in the optimal solution if we use more insulin, then more glucagon is also used. This is also consistent with the observation that with the dual drug therapy (insulin and glucagon) we can simultaneously improve ∆, G min , and G max .
Panel 4E shows a projection of the Pareto front on the (φ G , ∆) plane. Also in this case, the ReMF front dominates the ReME one, i.e., a pulsatile therapy gives better results than a continuous one in terms of ∆ by also using lower amounts of the two drugs (smaller φ G , and thus smaller φ I due to the linear relationship found in Fig. 4D) .
The Pareto front is monotonically decreasing in Fig. 4E which indicates a trade-off between the total amount of drugs used and the achievable glucose control performance. We choose the value of α G for which the ratio between the increase in ∆ and the decrease in φ G is minimized, i.e., α G = 10 −1 for the ReMF problem and α G = 1 for the ReME problem, which are indicated by dashed circles in the figure. Figures 5A and 5B show the results of the optimal control problem for α p = 10 2 , α I = 1 and α G = 10 −1 when p = 1; and α p = 10 4 , α I = 1 and α G = 1 when p = 2. In Fig. 5A we plot the time evolution of glucose G(t). The blue curve corresponds to the solution of the ReMF problem when only insulin is used (the blue curve in Fig. 3A) . The red and green curves Fig 3. A) The time evolution of glucose G(t) (in mg/dL). The blue curve corresponds to the pulsatile optimal insulin supply rate u I (t) (shown in B) obtained by solving the ReMF problem. The magenta curve corresponds to the continuous optimal insulin supply rate u I (t) (shown in B) obtained by solving the ReME problem. The orange curve is the time evolution of G(t) corresponding to the standard therapy (20.88 U of subcutaneous insulin injected 30 minutes before the time of the meal). B) Time evolution of the optimal insulin infusion rates u I (t) (in U/min). Color code is consistent with A. C) Cumulative insulin supply r I (t) (in U) as a function of t. 
We select α G = 10 −1 for the REMF problem and α G = 1 for the ReME problem, which are indicated by dashed circles in the figure.
correspond to the solution of the ReMF and the ReME problems for the dual drug therapy. We observe that G(t) reaches the desired level G d faster if we use both insulin and glucagon as control inputs, compared to the case that only insulin is used. We also see that in this case both G max decreases and G min increases. We therefore conclude that the therapy with both insulin and glucagon performs better than the therapy with only insulin, as the risks for both hypoglycemia and hyperglycemia are reduced and glucose fluctuations are suppressed. In Fig.5B we plot the optimal insulin infusion rates and in Fig. 5C we plot the cumulative insulin supply r I (t) as a function of time t. We observe that for the ReMF problem, the pulse in insulin appears at t = 41 minutes in the case that both insulin and glucagon are used (19 minutes before the meal), whereas the pulse appears at t = 26 minutes when only insulin is used. From Fig. 5D , we see that, for the ReMF problem, the glucagon delivery function is pulsatile with a first pulse appearing at t = 120 min (one hour after the meal) and a second pulse appearing at t = 190 min (2 hours and 10 minutes after the meal). Looking at Fig, 5E we see that the larger amount of glucagon is delivered with the first shot. Different from the only insulin problem, the glucose behavior is noticeably different between the ReMF solution and the ReME solution. As expected, the solutions of the ReME problem are continuous, but a slightly worse result is obtained (specifically, the green curve has bigger oscillations in panel A) with a slightly greater total amount of both insulin and glucagon (see panels C and D). Figure 5 suggests a possible ad-hoc dual drug therapy could be used as an alternative to the standard therapy. Rather than administering an insulin injection half an hour before the meal, better glucose regulation can be achieved with a larger insulin injection 20 minutes before the meal followed by a glucagon injection 60 minutes after a meal. The insulin injection of the new dual drug therapy is 50% larger than the one used in the standard therapy, which is consistent with the relation between φ I for the insulin only ReMF optimal solution and the one used in the dual drug therapy. To compute the glucagon dosage, we use the linear relationship we highlighted in Fig. 4D , that is,
Obviously, glucagon should be used only when the obtained φ G is positive, as the dual drug therapy is only useful when at least 14 units of insulin are used to counteract a 70 grams-of-glucose meal (i.e., an insulin-to-carb ratio of at least 2:10). In Fig. 6 we report the glucose response for the standard therapy to counteract a meal consisting of 70 grams of glucose (for the particular patient considered this amounts to 20 units of insulin half an hour before the meal) and the proposed ad-hoc dual drug therapy (which consists of 30 units of insulin 20 minutes before the meal and 0.58 mg of glucagon one hour after the meal). The two therapies are reported in orange and cyan, respectively. We observe that the ad-hoc dual drug therapy therapy performs better with respect to all of the proposed measures as opposed to the standard insulin based therapy.
Robustness analysis
We now analyze how the optimal control therapies we have proposed are robust with respect to model uncertainties, which is a fundamental step for implementation of model based control. We perturb the model parameters up to 10% of their values,
where Θ i ∈ Θ G b and ϕ is a random number from a normal distribution N (0, 0.033 2 ). We then apply the optimal insulin and glucagon dosing, calculated for the unperturbed system, to 100 perturbed systems. This is analogous to testing the computed optimal control therapy on a number of different patients, where each patient is slightly different from the model. The results of this study are illustrated with a Control Variability Grid Analysis (CVGA), see Fig. 7 . The CVGA provides a simultaneous visual and numerical assessment of the overall quality of glycemic control strategies in terms of the achieved minimum/maximum glucose values in the entire population of (simulated or real) patients, as described in [2, 3] . In Fig. 7 , points in the light green region indicate accurate blood glucose control while points in the dark green regions indicate the patient is not immediately at risk of either hypoglycemia and hyperglycemia Points in the top two yellow/orange regions indicate the patient is at an elevated risk of hyperglycemia and points in the the right two yellow/orange regions indicate the patient is at an elevated risk of hypoglycemia. Finally, points in the red corner region indicate the patient is at an elevated risk of both hyperglycemia and hypoglycemia. Each point reported in the figure is a plot of G max vs. G min . Here, the black dots correspond to the glucose response when a certain therapy is applied to the 100 simulated patients obtained through the proposed parameter perturbation. Cross symbols indicate application of the optimal control therapies to the unperturbed systems.
For the insulin only problem (ReMF in Fig. 7A and ReME in Fig. 7B ) we find the control is 93% and 91% accurate, respectively. For the insulin and glucagon problem (ReMF in Fig. 7C and ReME in Fig. 7D ) we find the control to be more accurate than with insulin alone, 95% and 98% accurate, respectively. The least robust control is obtained with the standard therapy (shown in Fig. 7E , attaining only 86% accuracy. Finally, our ad hoc dual drug therapy achieves 97% accuracy, out performing both the standard therapy and the insulin only optimal therapies. Note that while the ReMF optimal solution using both insulin and glucagon may perform better than our ad hoc dual drug therapy in terms of all the metrics we proposed, the ad hoc therapy is more robust Note that in the dual drugs therapies (Figs. 7C and 7D) the optimal solution is not in the center of the cloud likely because it uses a lot of the model information. This tells us that these optimal solutions can be used as a reference but hard to implement in the presence of disturbances and uncertainties. Finally, we observe that all of the control techniques we considered are robust against perturbations.
Discussion
In this paper, we have considered an FDA approved Glucose-Insulin-Glucagon mathematical model that captures the key features of Type I diabetes. The model accurately describes how the body responds to exogenously supplied insulin and glucagon in patients with Type I diabetes. We used this model in the design of an optimal control problem that provides a dosing schedule of either insulin or insulin and glucagon combined to regulate the blood glucose index (BGI) while limiting the total amount of insulin and glucagon administered. As we have chosen the most realistic blood glucose model currently available, which is necessarily complex, and the fact we have chosen to minimize an appropriate, problem specific metric (BGI), there does not exist an analytic solution to the optimal control problem. Thus, we have used the numerical optimal control software PSOPT to solve the optimal control problem. While the numerical solutions only holds for the precise set of parameters chosen, Θ G b , the solutions we obtain G min Fig 7. Robustness of the optimal control solution against parameter perturbations of the system and CVGA in the G min , G max plane. The analysis is performed for A) ReMF (p = 1) problem with only insulin provided, B) ReME (p = 2) problem with only insulin provided, C) ReMF (p = 1) problem with both insulin and glucagon provided, D) ReME (p = 2) problem with both insulin and glucagon provided, E) the standard therapy, and F) the proposed ad-hoc dual drug therapy. Cross symbols indicate application of the optimal control therapies to the unperturbed systems. provide insight into the best possible glucose regulation with insulin or with insulin and glucagon. Thus, our investigation provides an upper threshold that no alternative therapy (such as MPC, PID, etc.) can cross with respect to our family of objective functions.
Two distinct regulation problems were considered: the minimum fuel problem (ReMF) which yield pulsatile (shot-like) type solutions and the minimum energy problem (ReME) which yield longer duration with smaller rate type solutions. This allows us to compare standard therapies which are typically composed of a shot of insulin with therapies in which insulin is given continuously more indicative of pumps. Incredibly, we find that shot therapies outperform continuous therapies. Even though our results have been obtained using a pulsatile model of the meal, we have checked that they do not qualitatively change for alternative models of the meal (for example, a meal that that is consumed over a window of 15 minutes).
For each of the two problems, we solve the optimal drug dosing schedules when only insulin is available and when both insulin and glucagon are available. The solution of the insulin only ReMF problem, astoundingly, is nearly equal to the standard method of insulin based glucose regulation. Similarly, the solution of the ReMF problem when insulin and glucagon are available is also pulsatile, except that the amount of insulin administered is larger and closer to the meal, while the glucagon shot occurs about an hour after the meal.
The solution for the ReME problem when insulin only is available as well as when both insulin and glucagon are available is different from the ReMF solution in that, rather than being pulsatile, the insulin and possibly glucagon are delivered at a slower rate over a longer period of time. Nonetheless, the total amount of insulin and possibly glucagon is about the same, and the peak of the longer delivery time occurs approximately at the same time as the shot delivered according to the ReMF problem. The obtained glucose profiles for the optimal ReMF and ReME problem solutions do not differ too much: taken together with the above statements, it implies that the amount of insulin and glucagon, and the peak times of delivery, are the more important factors with respect to the optimal solutions.
Combining the above results, we suggest the following ad hoc therapy to act as a rule of thumb when insulin and glucagon are used in combination. The therapy can be stated as follows: Administer a shot of insulin (with 50% more insulin than what the standard therapy dictates for the planned meal) 20 minutes before eating. Administer a shot of glucagon of an amount dictated by Eq. (11) one hour after completing the meal. This therapy must be used with caution as the amount of insulin injected can lead to hypoglycemia if the shot of glucagon is not administered as well.
All optimal dosing schedules we computed were tested for robustness with respect to random perturbations to the parameters, to simulate our dosing schedule administered to a population of patients with type I diabetes. These results are shown in CVGA plots where we see that all patients remain within the green zones, and most remain within the healthiest region.
The optimal controls we compute anticipate the presence of a meal in terms of time and amount. This is somewhat undesirable, as the recent improvements in diabetes therapy have moved towards devices that do not require the user to provide information about the meals. Our results emphasize the importance of knowing when meals will occur, and that new dosing schedules would benefit from at least some knowledge of meals. This suggest that a non/negligible improvement can be achieved if the pump can in someway learn the using of the patient.
